Projects
Project name
"Nanomedicine"- FY 2018 Japan-Spain Joint call for Strategic International Collaborative Research Program (SICORP)
Research and Development Theme
Drug delivery targeting Brain CPT1: a novel nanomedicine-based approach to fight obesity and cancer (COnCorD)
Time Period
Jan. 1, 2019 ～ Dec. 31, 2021
Research and Development Representative
Senior Research Scientist
Innovation Center of NanoMedicine
Sabina Quader
Research and Development Representative (Spain)
Universidad Internacional de Cataluña
Rosalía Rodríguez-Rodríguez
Outline
To develop and use of new nanomedicine-based therapeutic approaches directed to specific cells of the brain and to fight against obesity and brain tumors focusing on the brain lipid metabolism’s key enzyme CPT1.
Project name
Research Program on Hepatitis
Research on the Innovative Development and the Practical Application of New Drugs for Hepatitis B
Research and Development Theme
Comprehensive development of innovative therapeutics aiming at complete inactivation of HBV genome in liver by genome editing technology applicable to personalized medicine
Co-Research and Development Theme
Development of RNA carrier targeting the liver
Time Period
FY2017-FY2021
Research and Development Representative
Project Leader
Genome Medical Science Project, Research Institute,
The Research Center for Hepatitis and Immunology Department of Liver Diseases,
National Center for Global Health and Medicine
Masashi Mizokami
Co-Researcher
Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka
Outline
Our aim is to treat Hepatitis B by liver specific delivery of a messenger RNA (mRNA) encoding a genome editing enzyme to inactivate the hepatitis B virus genome. To achieve this goal, mRNA should be efficiently delivered to hepatocytes after intravenous injection, while avoiding clearance mechanisms and degradation during circulation. We are designing innovative nanomachines to protect and deliver mRNA.
Project name
"Project for Cancer Research And Therapeutic Evolution" (P-CREATE)
Research and Development Theme
Development of innovative cancer treatment methodologies based on drug delivery system
Co-Research and Development Theme
Development of nanoDDS for delivery of tumor microenvironment-targeted drugs and nucleic acids medicines.
Time Period
Apr. 1, 2016 - Mar. 31, 2021
Research and Development Representative
Professor, Tokyo Institute of Technology
Nobuhiro Nishiyama
Co-Researcher
Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka
Outline
In this project, we are developing 3 key technologies, nano-scaled drug delivery systems (nanoDDS), new drug candidates and evaluation methodologies through multidisciplinary collaboration by experts of DDS, molecular oncology and clinical oncology. This project is aimed to realize innovative cancer diagnostic and therapeutic systems targeting the network of cancer cells. The role of the researchers in iCONM is to develop nanoDDS for new drug candidate and establish their evaluation methods utilizing in vivo confocal laser scanning microscopy.
<< Past Projects >>
Project name
Research Program on Hepatitis
Research on the Innovative Development and the Practical Application of New Drugs for Hepatitis B
Research and Development Theme
Development of new therapy for the elimination of HBV DNA in the liver based on gene editing and nano delivery systems
Co-Research and Development Theme
Development of liver-targeting drug delivery system
Time Period
Apr. 1, 2016 - Mar. 31, 2017
Research and Development Representative
Project Leader
Genome Medical Science Project, Research Institute
National Center for Global Health and Medicine
Masashi Mizokami
Co-Researcher
Director General of the Innovation Center of NanoMedicine
Kazunori KataokaKawasaki Institute of Industrial Promotion
Principal Research Scientist at the Innovation Center of NanoMedicine
Keiji Itaka
Outline
We develop liver-targeting mRNA delivery system aiming at a new therapy for the elimination of HBV DNA in the liver. We design the mRNA-loaded nanomachine, evaluate its transfection efficiency and safety, and investigate the the therapeutic effect on HBV-infected model mice.
Project name
Practical Research for Innovative Cancer Control
Part3: Research and development of new drug to fulfill unmet medical needs
Research and Development Theme
Practical application for a novel nucleoside therapy targeting PRDM14 to overcome intractable breast and pancreatic cancer.
Co-Research and Development Theme
Development of delivery system for nucleic acids medicine
Time Period
Apr. 1, 2016 - Mar. 31, 2017
Research and Development Representative
Project Associate Professor, Center for Antibody and Vaccine Therapy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo
Hiroaki Taniguchi
Co-Researcher
Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka
Outline
This project is aimed to develop new nucleic acids medicine targeting PRDM14 for the treatment of intractable triple negative breast cancer and pancreatic cancer. We are developing polymeric delivery system of siRNA targeting PRDM14.
Project name
Practical Research for Innovative Cancer Control
Part3: Research and development of new drug to fulfill unmet medical needs
Research and Development Theme
Research on development of innovative therapeutic methods targeting solid cancer stem cells
Co-Research and Development Theme
Development of drug delivery system (DDS) which targeted at CD44 pathway of Cancer stem cells.
Time Period
Apr. 1, 2016 - Mar. 31, 2017
Research and Development Representative
Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery,
Professor Masaki Mori
Co-Researcher
Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka
Outline
This project is aimed to develop new therapeutic methods to eradicate cancer stem cells towards overcoming intractable digestive cancers such as pancreatic cancer and metastatic colon cancer. We are developing drug delivery system for targeting cancer stem cells.
Project name
Practical Research for Innovative Cancer Control
Part3: Research aiming at reinforcing scientific basis and developing to next phase for practical application of innovative cancer diagnostic and therapeutic drugs
Research and Development Theme
Clinical development of nucleic acid medicine for refractory gastrointestinal cancer
Co-Research and Development Theme
Evaluation of DDS (OUM302)
Time Period
Apr. 1, 2017 - Mar. 31, 2019
Research and Development Representative
Professor, Department of Gastroenterological Surgery, Graduate School of Medicine,
Osaka University
Mori Masaki
Co-Researcher
Director General of the Innovation Center of NanoMedicine
Kazunori Kataoka
Outline
We screen effective nucleic acid medicine for refractory gastrointestinal cancer and enclose it in a drug delivery system. Then we develop nucleic acid medicines with high antitumor effecacy by protection of nucleases in the blood and accumulation in cancer. And we proceed a doctor-initiated clinical trial.
Project name
the Strategic Research Program for Brain Sciences (the SRPBS)
Integrated Research on Depression, Dementia and Development Disorders
Research and Development Theme
Molecular imaging diagnosis of Alzheimer’s disease through the creation of blood-brain barrier-crossing beta-amyloid oligomer antibody, Explaining development of the treatment and pathogenic mechanism
Co-Research and Development Theme
Structural and functional evaluation of GLUT1 bound ligand molecule that allows for efficient delivery of antibodies within the brain
Time Period
Apr. 1, 2016 - Mar. 31, 2020
Research and Development Representative
Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
Professor Takanori Yokota
Co-Researcher
Director General of the Innovation Center of NanoMedicine
Kazunori KataokaKawasaki Institute of Industrial Promotion
Visiting Scientist at the Innovation Center of NanoMedicine
Yasutaka Anraku
Outline
This theme has a focus on the creation of a BBB-crossing ABO antibody, using the Aβ oligomer antibody (ABO antibody) that team researcher Mr. Matsubara - who is in Phase I in the U.S. - developed, and narrowed the focus to the beta-amyloid (Aβ) oligomer, which is a probable pathogenetic molecule of Alzheimer’s Disease (AD) as the target molecule. Also, the development an Aβ oligomer PET/MRI and giving a diagnosis while analyzing Aβ oligomer pathology.
The results show that it is now possible to diagnose of early onset - and before pathogenesis - of AD, and sort out which patients are to be treated, as well as the development of a companion diagnostic that makes it possible for repeat evaluation. This will make a “theranostics drug” that has both therapeutic and diagnostic functions a reality, which will be innovative and ideal dimentia drug development that agrees with advanced innovative drug development concepts that next-generation innovative drug development demands.
Project name
Technology development program for countermeasures against viruses and other infectious diseases
Research and Development Theme
Development of a portable rapid testing device for the virus infectious diseases
Time Period
2020.12-2021.3
Research and Development Representative
The graduate school of engineering, Department of materials engineering, University of Tokyo, Professor
Takanori Ichiki
Co-Researcher
Deputy Principal Research Scientist
Innovation Center of NanoMedicine
Shingo Ueno
Outline
Development of a prototype of portable rapid testing device for the virus infectious diseases and quantitative verification of its usefulness.